QINTIE 2018-01-31 08:16
三门峡康瑞药业有限公司注册地址:河南三门峡;经营范围:药用果胶、果胶铋生产与销售;需求:公司整套手续转让;与投资者合作生产,引进资金用于购置设备及厂房建设。   [更多]
悬赏:
悬赏
¥30000000.00
载入中...
richard16 2018-05-28 11:43
该项目旨在设计和制造一种双室预填充单剂量注射器的初始原型。这些设备将在全球健康项目中使用,要求注射用药品使用简单,复溶直观,这些药品需要在偏远地区室内环境中以干燥状态(粉末或冻干饼状物)储存。本征集标书例举了该设备的两个实际用例:低技能医护人员在挨家挨户的麻疹-风疹疫苗强化免疫中使用,以及由患者可在家中或其他非临床环境中自行注射新一代长效可注射避孕药。该设备应能够在传统医疗机构之外实现安全注射,并满足例举的两个实际用例之一的最低要求。理想情况下,所建议的设备将满足并超过这两个用例的最低要求。 为了满足实际使用需求,这些设备需要满足几个关键要求: 轻便,坚固且紧凑,便于运输,存储和使用,包括最后一英里的设置,例如偏远地区的房屋之间的搬动 简单直观,适用于低技能医护人员使用和/或自我注射 确保冻干或粉状药物或疫苗产品准确复溶与给药 能与各种需无菌注射的制剂兼容,包括药物,生物制剂和疫苗 与无菌条件下的灌装设备兼容,并且能够确保药品在储存,复溶和给药环节无菌 包含内置防护措施以防止包括针头在内的注射器重复使用 制造和灌装成本低,可在全球健康项目中广泛采用 征寻提案的重点是早期研究和创建未来用于人体试验研究的原型设备。预计将于2019年1月颁发3-5个奖项,每个奖项的奖金从10万美元到25万美元不等。目标资助期限约为6个月。 本轮方案征寻为第一阶段 - 成功的原型可能会就用户接受度的测试,中试规模生产以及后续开发得到进一步支持。 请直接将所有申请文件提交至 dualchamberrfp@gatesfoundation.org 您的提交内容应仅包括完整的概念备忘录。 其他附件,包括申请信和补充信息将不被接受或审评。 征寻提案指南(征寻提案概述) 完整标准(可用于每个实际用例的特定组合药物注射器标准 - 麻疹 - 风疹疫苗和注射避孕药具) 与营利性组织合作(对有兴趣获得资助的营利性公司进行介绍性概述) 概念备忘录模板(用于提交方案的模板)   [更多]
悬赏:
悬赏
¥3100000.00
载入中...
wuji 2013-08-12 14:40
需求内容:由透明质酸均属于多糖类物质,应用该原料交联合成的水凝胶可避免异基因蛋白组分的凝胶带来的免疫学疑虑,部分进口厂家透明质酸凝胶产品吸水性强,与皮肤组织相容性好,可塑性强,可以根据不同需要塑性。 技术指标: 1. 体内停留时间可达到6个月以上 2. 有较好的细胞相容性、组织相容性 3. 可用于颜面部注射 4. 颗粒度均一,并可根据需要调节生产不同颗粒度的凝胶 5. 生产成本在200元/毫升以下 6. 1年内可获SFDA批准用于临床试验(含已获SFDA批准)   [更多]
悬赏:
悬赏
¥200000.00
载入中...
xiangwen521 2015-02-02 12:33
标题:重金求购卡巴克络生产工艺或者原料 英文名称: Carbazochrome 中文名称: 卡巴克络 MF: C10H12N4O3 MW: 236.23 CAS: 69-81-8 要求时间:请在2015年12月之前 交稿方式:直接点击交稿在线交稿就是了,我会每天过来看的,谢谢各位药智的战友们   [更多]
悬赏:
悬赏
¥100000.00
载入中...
lyj19721101 2015-07-16 15:12
罕见癌症研究基金会(RCRF),致力于通过战略投资和创新合作进行基础治疗罕见的癌症,和美国文化募捐组织(ATCC),世界上最大的非营利性细胞株库,建立神经内分泌肿瘤细胞株收集目录。肠道良性肿瘤和胰腺神经内分泌肿瘤(PNET)需求一种新疗法的研究和发展,即在体内原发性肿瘤中建立新的细胞株。 为了刺激发展新的良性肿瘤和PNET细胞系,该基金会是高兴地宣布第二次开放竞争十个人奖项:开发人员的第一个新的细胞系在每个疾病(肠道良性肿瘤和PNET)将获得100000美元,开发者的第二,第三,第四,第五个新细胞系在每个疾病将会收到50000美元。原文如下:https://www.innocentive.com/ar/challenge/9933756 The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Caring for Carcinoid Foundation therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery. Source: InnoCentive Challenge ID: 9933756 Challenge Overview This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use. To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual   [更多]
悬赏:
悬赏
¥600000.00
载入中...
06070013 2013-08-02 15:58
两个药品试行标准转正,要求100%通过,寻求代理,非诚勿扰。   [更多]
悬赏:
悬赏
¥100000.00
载入中...
qing_zyq 2018-05-22 09:35
本公司因项目需要,对外委托基因毒性杂质研究:肼基、叠氮、氯代烷烃、酰氯类、氰化物等;请有研究能力的公司与我们联系。 项目要求: 1、完成以上基因毒性杂质的方法学开发、验证资料; 2、研究机构具有与实验相匹配的设备,并经过验证; 3、受委托机构可以接受审计及研制现场核查; 4、研究资料符合数据完整性要求;   [更多]
悬赏:
悬赏
¥100000.00
载入中...
wuxian3140 2015-10-16 12:41
品种1:抗肿瘤类,50ml西林瓶 品种2:抗生素类,5ml西林瓶 品种3:抗生素类,10ml西林瓶 以上3个品种均为冻干粉针,我公司需要寻找冻干车间,制备3批中试样品(3批注册批),主要服务是提供中试生产场地及协助我们进行中试3批生产。希望能提供服务的公司与我联系,服务价格我预估在10万左右(每个品种10万,只是我个人预估的),实际成交价格可以面谈。   [更多]
悬赏:
悬赏
¥100000.00
载入中...
lyj19721101 2015-02-06 13:34
排行世界的第五大的制药公司寻找合作伙伴,要求提供多种大环结构药物与合成技术,寻找有关大环领域的新药发现。希望此公司提供化学详细的3 d模型。具体请链接:https://www.innocentive.com/ar/challenge/9933642 The Seeker, a top-five big pharma company, is looking for collaboration partners with expertise in the area of macrocycle drug discovery. Specifically, three key areas are of interest: Chemistry partners with access to diverse macrocyclic structures & synthetic expertise In-silico chemistry partners with access to high-throughput 3-D models suitable for macrocycles In-vitro ADME experts with access to membrane systems, beyond PAMPA and Caco-2 This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (about 2–4 pages including contact information) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, the Seeker may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the time frame agreed upon.   [更多]
悬赏:
悬赏
¥90000.00
载入中...
lyj19721101 2015-03-13 14:16
弥漫性大B细胞淋巴瘤(DLBCL)是一种最常见的非霍奇金淋巴瘤,诊断病例在美国约占淋巴瘤的30%。它是一种特异质性疾病。由于临床多样性和复杂性,又有新的突变在某些难治性患者身上被发现。阿斯利康需要创建一种弥漫性巨大B细胞淋巴瘤的合适的临床模型。 具体链接在:https://www.innocentive.com/ar/challenge/9933016 AstraZeneca Challenge: Developing Clinically-Relevant Models for Diffuse Large B Cell Lymphoma (DLCBL) TAGS: AstraZeneca, Physical Sciences, Life Sciences, Nature, Requests for Partners and Suppliers, Chemistry, RTP AWARD: See details | DEADLINE: 6/02/15 | ACTIVE SOLVERS: 9 | POSTED: 3/04/15 Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and accounts for up to 30% of newly diagnosed cases in the United States. It is a heterogeneous disease which in part appears to be driven by chronic activation of key survival pathways. A limited number of DLBCL cell lines are available, however there are gaps, and specific patient subtypes are not represented. To add to the complexity of clinical diversity, new mutations are being identified in certain treatment-resistant patients. AstraZeneca is interested in innovative proposals to create suitable preclinical models of DLBCL. This is a Reduction-to-Practice Challenge that requires a written proposal and experimental proof-of-concept data (and/or sample delivery). The Challenge has a special award structure. Whether creating a model for DLBCL or a model of acquired resistance to ibrutinib, up to $10,000 will be designated for solutions that highlight novel technologies to generate in vitro cell lines, whereas up to $25,000 will be awarded for submissions that successfully utilize patient-derived tissues.   [更多]
悬赏:
悬赏
¥90000.00
载入中...
发布需求,坐等药智客上门
  • 安全可靠,先验收再正式付款
  • 性价比超高,节省一半费用
  • 80%的需求得到了圆满解决
立即发布需求

推荐任务